Login to Your Account

Other news to note

Wednesday, February 12, 2014

Pharmaessentia Corp., of Taiwan, and Kinex Pharmaceuticals Inc., of Buffalo, N.Y., said they executed a new licensing agreement granting Pharmaessentia exclusive development and commercial rights to Oraxol and Oratecan in Taiwan and Singapore. Kinex will receive an undisclosed up-front payment, milestones and royalties, and Pharmaessentia also agreed to conduct clinical studies in Taiwan to contribute to the global registration programs for the drugs.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription